Syndax Pharmaceuticals
SNDX
227 hedge funds and large institutions have $1.56B invested in Syndax Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 72 reducing their positions, and 28 closing their positions.
100% more call options, than puts
Call options by funds: $25M | Put options by funds: $12.5M
63% more capital invested
Capital invested by funds: $953M → $1.56B (+$603M)
46% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 28
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
13% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 72
5% more funds holding
Funds holding: 216 → 227 (+11)
0.85% less ownership
Funds ownership: 118.22% → 117.38% (-0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$24.6M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$18M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$15.8M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$24M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$15.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14.3M |
| 4 |
SC
Stempoint Capital
New York
|
-$13.2M |
| 5 |
EP
Eversept Partners
New York
|
-$7.83M |
SNDX Hedge Fund Activity: Q3 2025 in Review
227 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2025, worth a combined $1.56B — up 63% from $953M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SNDX positions and 28 closed out — a net gain of 13 holders — while 81 added to existing stakes and 72 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $27.8M. The largest seller was BlackRock, cutting an estimated $24M.
- 227 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2025, up from 216 in Q2 2025.
- Funds reported $1.56B of Syndax Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
- 41 funds opened new Syndax Pharmaceuticals positions in Q3 2025 and 28 closed out, a net change of +13 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2025 was Point72 Asset Management, an estimated $27.8M added.
- The largest Syndax Pharmaceuticals seller in Q3 2025 was BlackRock, an estimated $24M sold.
Based on aggregated 13F filings for Q3 2025.